- News & Features
ACR issues policy principals that urge federal officials to adopt as they consider drug policy changes affecting the health care of chronically ill Americans.
Lupus patients with early-onset disease are less likely than those with late-onset lupus to suffer from lung disease.
A systematic review of six studies, published recently in Arthritis Care & Research, evaluates the effectiveness of methotrexate in treating chikungunya.
International rheumatology, dermatology, neurology, and pediatric groups have endorsed the new criteria.
Ultrasound and MRI have been shown to be more sensitive than clinical examination in detecting synovitis, both in active disease and in remission.
Younger, thinner rheumatoid arthritis patients, with lower disease activity and better scores on a certain health assessment, have a better chance of achieving remission when combining the tumor-necrosis factor (TNF) inhibitor etanercept (enbrel) with methotrexate induction therapy.
Ever wonder what life is like for those living chronic and invisible diseases? Learn about the invisible struggles people with chronic disease face.
Higher MBDA scores yielded statistically significant associations with higher serious infection rates and significantly higher rates of heart disease.
On Dec. 14, Pfizer, which makes tofacitinib (Xeljanz), announced that the FDA had approved the drug for PsA.
In 2017, CreakyJoints lived up to our mantra of “bringing arthritis to its knees", by increasing support, education, advocacy, and research activities.
These findings suggest that there is a window of opportunity to treat patients with undifferentiated arthritis early, to delay subsequent progression to RA.